

Drawing Correction and Formal Drawings

The Office Action included a Form PTO 948, Notice of Draftsperson's Patent Drawing Review. The Notice indicates that drawings filed on June 29, 2000, the filing date of the application, were reviewed by the Draftsperson.

A Transmittal of Proposed Drawing Corrections and New Formal Drawings, with Formal Drawings (sheets 1/4-4/4) was filed on September 14, 2000. Thus, it appears that the Formal Drawings have not been reviewed by the Draftsperson.

Acknowledgment of approval of the proposed drawing corrections and acceptance of the Formal Drawings filed on September 14, 2000 is respectfully requested in the next Office Communication.

Information Disclosure Statement


A Second Supplemental Information Disclosure Statement was filed on July 23, 2002, and a Third Supplemental Information Disclosure Statement is being filed concurrently. Acknowledgment of consideration of the information provided in the Second and Third Supplemental Information Disclosure Statements is requested in the next Office Communication.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By   
Robert H. Underwood  
Registration No. 45,170  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: *March 19, 2003*

MARKED UP VERSION OF AMENDMENTSClaim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

Claims 16, 17 and 61-64 have been amended. New Claims 85-88 have been added to the application.

16. (Five Times Amended) An isolated human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of IP-10 and Mig, [~~and can mediate cellular signalling and/or a cellular response in response thereto,~~] and [~~wherein said protein or variant~~] is encoded by a nucleic acid which hybridizes to a second nucleic acid selected from the group consisting of the complement of SEQ ID NO:1 and the complement of the open reading frame of SEQ ID NO:1 under high stringency wash conditions of 2X SSC, 0.1% SDS at room temperature for ten minutes followed by two washes in 1X SSC, 0.1% SDS at 65°C for thirty minutes and a final wash in 0.5X SSC, 0.1% SDS at 65°C for ten minutes.
17. (Four Times Amended) The isolated human CXCR3 protein or functional variant thereof of Claim 16, wherein said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of human IP-10 and human Mig.
61. (Four Times Amended) A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of IP-10 and Mig, [~~and can mediate cellular signalling and/or a cellular response in response thereto,~~] and [~~wherein said CXCR3 protein or variant~~] is encoded by a nucleic acid which hybridizes to a second nucleic acid selected from the group consisting of the complement of SEQ ID NO:1 and the complement of the open reading frame of SEQ ID NO:1 under high stringency wash conditions of 2X SSC, 0.1% SDS at room temperature for ten minutes followed by two

washes in 1X SSC, 0.1% SDS at 65°C for thirty minutes and a final wash in 0.5X SSC, 0.1% SDS at 65°C for ten minutes.

62. (Twice Amended) The fusion protein of Claim 61, wherein said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of human IP-10 and human Mig.
63. (Twice Amended) An isolated human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein the amino acid sequence of said CXCR3 protein or functional variant is at least about 90% identical to that of the protein shown in Figure 2 (SEQ ID NO:2), said CXCR3 protein or functional variant comprises the extracellular N-terminal segment of the protein shown in Figure 2 (SEQ ID NO:2), and said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of IP-10 and Mig [~~and mediate cellular signalling and/or a cellular response in response thereto~~].
64. (Twice Amended) A fusion protein comprising a human CXC Chemokine Receptor 3 (CXCR3) protein or functional variant thereof, wherein the amino acid sequence of said CXCR3 protein or functional variant is at least about 90% identical to that of the protein shown in Figure 2 (SEQ ID NO:2), said CXCR3 protein or functional variant comprises the extracellular N-terminal segment of the protein shown in Figure 2 (SEQ ID NO:2), and said CXCR3 protein or functional variant [~~can bind~~] binds one or more chemokines selected from the group consisting of IP-10 and Mig [~~and mediate cellular signalling and/or a cellular response in response thereto~~].